Apotex Asks DC Circ. To Stay Teva's Hyzaar Exclusivity

Law360, New York (April 6, 2010, 4:05 PM EDT) -- Apotex Inc. has asked a federal appeals court to bar Teva Pharmaceuticals USA Inc. from gaining a 180-day exclusivity period on generic versions of Merck & Co. Inc. hypertension drugs Hyzaar and Cozaar.

Apotex filed an emergency motion in the U.S. Court of Appeals for the District of Columbia Circuit on Monday, seeking a stay of the U.S. Food and Drug Administration's award of exclusivity to Teva, as well as a stay on approval of all abbreviated new drug applications related to the drugs.

The FDA...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.